LY4584180 + Rituximab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin's
Conditions
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Trial Timeline
Feb 1, 2026 → Dec 1, 2029
NCT ID
NCT07226843About LY4584180 + Rituximab
LY4584180 + Rituximab is a phase 1 stage product being developed by Eli Lilly for Lymphoma, Non-Hodgkin's. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07226843. Target conditions include Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07226843 | Phase 1 | Recruiting |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin's